

CERTIFICATE

Survey of 09 September 2022

You have fulfilled the requirements of the External Quality Assessment with the following analysis

Autoimmune Diseases 13 - Antiphospholipid Syndrome (275):

Validity 24 months:

anti-Cardiolipin (IgG)

anti-Cardiolipin (IgM)

anti- β 2-Glycoprotein (IgG)

anti- β 2-Glycoprotein (IgM)

(R) analysis is subject to the RiliBÄK

Participant:

49579

Doc. MUDr., CSc. Tomas Kvasnicka

Vseobecná fakultní nemocnice v Praze

Trombotické centrum - Lab. dedic. vad hemostazy

Karlovo náměstí 554/32

128 08 Praha

Düsseldorf, 05 October 2022



Prof. Dr. med. Michael Spannagl
(Head of Reference Institution)



Dr. rer. nat. Martin Blüthner
(Adviser)

CERTIFICATE OF PARTICIPATION

Survey of 09 September 2022

You have participated in the External Quality Assessment with the following analysis


Autoimmune Diseases 13 - Antiphospholipid Syndrome (275):

anti-Cardiolipin (IgG)
anti-Cardiolipin (IgM)
anti- β 2-Glycoprotein (IgG)
anti- β 2-Glycoprotein (IgM)

(R) analysis is subject to the RiliBÄK

Participant:
49579
Doc. MUDr., CSc. Tomas Kvasnicka
Vseobecná fakultní nemocnice v Praze
Trombotické centrum - Lab. dedic. vad hemostazy
Karlovo náměstí 554/32
128 08 Praha

Düsseldorf, 05 October 2022



Prof. Dr. med. Michael Spannagl
(Head of Reference Institution)



Dr. rer. nat. Martin Blüthner
(Adviser)